253 related articles for article (PubMed ID: 19430532)
61. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures.
Platet N; Liu SY; Atifi ME; Oliver L; Vallette FM; Berger F; Wion D
Cancer Lett; 2007 Dec; 258(2):286-90. PubMed ID: 17977646
[TBL] [Abstract][Full Text] [Related]
62. Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3.
Guo R; Wu Q; Liu F; Wang Y
Oncol Rep; 2011 Jan; 25(1):141-6. PubMed ID: 21109969
[TBL] [Abstract][Full Text] [Related]
63. Expression of multidrug resistance genes in normal and cancer stem cells.
Shervington A; Lu C
Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
[TBL] [Abstract][Full Text] [Related]
64. Expression of distinct splice variants of the stem cell marker prominin-1 (CD133) in glial cells.
Corbeil D; Joester A; Fargeas CA; Jászai J; Garwood J; Hellwig A; Werner HB; Huttner WB
Glia; 2009 Jun; 57(8):860-74. PubMed ID: 19053060
[TBL] [Abstract][Full Text] [Related]
65. Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection.
Sgambato A; Puglisi MA; Errico F; Rafanelli F; Boninsegna A; Rettino A; Genovese G; Coco C; Gasbarrini A; Cittadini A
J Cell Physiol; 2010 Jul; 224(1):234-41. PubMed ID: 20333645
[TBL] [Abstract][Full Text] [Related]
66. Characterization of CD133+ parenchymal cells in the liver: histology and culture.
Yoshikawa S; Zen Y; Fujii T; Sato Y; Ohta T; Aoyagi Y; Nakanuma Y
World J Gastroenterol; 2009 Oct; 15(39):4896-906. PubMed ID: 19842219
[TBL] [Abstract][Full Text] [Related]
67. Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions.
Fang KM; Lin TC; Chan TC; Ma SZ; Tzou BC; Chang WR; Liu JJ; Chiou SH; Yang CS; Tzeng SF
Glia; 2013 Sep; 61(9):1402-17. PubMed ID: 23832679
[TBL] [Abstract][Full Text] [Related]
68. Expression and localisation of osteopontin and prominin-1 (CD133) in patients with endometriosis.
D'Amico F; Skarmoutsou E; Quaderno G; Malaponte G; La Corte C; Scibilia G; D'Agate G; Scollo P; Fraggetta F; Spandidos DA; Mazzarino MC
Int J Mol Med; 2013 May; 31(5):1011-6. PubMed ID: 23545719
[TBL] [Abstract][Full Text] [Related]
69. Prominin1 (CD133) as an intestinal stem cell marker: promise and nuance.
Montgomery RK; Shivdasani RA
Gastroenterology; 2009 Jun; 136(7):2051-4. PubMed ID: 19409288
[No Abstract] [Full Text] [Related]
70. Alpha2,3-Sialylation regulates the stability of stem cell marker CD133.
Zhou F; Cui C; Ge Y; Chen H; Li Q; Yang Z; Wu G; Sun S; Chen K; Gu J; Jiang J; Wei Y
J Biochem; 2010 Sep; 148(3):273-80. PubMed ID: 20551139
[TBL] [Abstract][Full Text] [Related]
71. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients.
Artells R; Moreno I; Díaz T; Martínez F; Gel B; Navarro A; Ibeas R; Moreno J; Monzó M
Eur J Cancer; 2010 Feb; 46(3):642-9. PubMed ID: 20005089
[TBL] [Abstract][Full Text] [Related]
72. Prominin-1 (CD133) is not restricted to stem cells located in the basal compartment of murine and human prostate.
Missol-Kolka E; Karbanová J; Janich P; Haase M; Fargeas CA; Huttner WB; Corbeil D
Prostate; 2011 Feb; 71(3):254-67. PubMed ID: 20717901
[TBL] [Abstract][Full Text] [Related]
73. Lgr5-positive cells are cancer stem cells in skin squamous cell carcinoma.
Liu S; Gong Z; Chen M; Liu B; Bian D; Wu K
Tumour Biol; 2014 Nov; 35(11):11605-12. PubMed ID: 25135431
[TBL] [Abstract][Full Text] [Related]
74. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas.
Immervoll H; Hoem D; Sakariassen PØ; Steffensen OJ; Molven A
BMC Cancer; 2008 Feb; 8():48. PubMed ID: 18261235
[TBL] [Abstract][Full Text] [Related]
75. Hypoxia promotes stem-like properties of laryngeal cancer cell lines by increasing the CD133+ stem cell fraction.
Wu CP; Du HD; Gong HL; Li DW; Tao L; Tian J; Zhou L
Int J Oncol; 2014 May; 44(5):1652-60. PubMed ID: 24573690
[TBL] [Abstract][Full Text] [Related]
76. Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival.
Wang XY; Penalva LO; Yuan H; Linnoila RI; Lu J; Okano H; Glazer RI
Mol Cancer; 2010 Aug; 9():221. PubMed ID: 20727204
[TBL] [Abstract][Full Text] [Related]
77. Expression profiling of CD133+ and CD133- epithelial cells from human prostate.
Shepherd CJ; Rizzo S; Ledaki I; Davies M; Brewer D; Attard G; de Bono J; Hudson DL
Prostate; 2008 Jun; 68(9):1007-24. PubMed ID: 18398820
[TBL] [Abstract][Full Text] [Related]
78. Expression of CD133 and other putative stem cell markers in uveal melanoma.
Thill M; Berna MJ; Grierson R; Reinhart I; Voelkel T; Piechaczek C; Galambos P; Jager MJ; Richard G; Lange C; Gehling UM
Melanoma Res; 2011 Oct; 21(5):405-16. PubMed ID: 21900792
[TBL] [Abstract][Full Text] [Related]
79. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.
Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C
PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156
[TBL] [Abstract][Full Text] [Related]
80. [Application of genome-wide genechip for screening and identifying genes related to CD133(+)CD200(+) colorectal cancer stem cells].
Zhang S; Li L; Huang Z; Xin X; Xiao B
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Dec; 33(12):1787-91. PubMed ID: 24369246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
